Aysun Karabay BAYAZIT, Ali ANARAT, Bahriye ATMIŞ, Engin MELEK

Linezolid-inducedthrombocytopeniaintwo patientswithrenaldysfunction

Linezolid, glikopeptidlerde dahil diğer antibiyotiklere dirençli gram pozitif bakterilere karşı etkin olan oksazolidinon grubu bir antibiyotiktir. Linezolid kullanımına bağlı görülen yan etkilerden birisi trombositopenidir. Trombositopeniye neden olan farklı birçok risk faktörü bildirilmesine karşın, bu yan etkinin nedeni tam olarak bilinmemektedir. Burada kliniğimizde kronik böbrek hastalığı tanısı ile izlenen ve linezolid tedavisi sırasında trombositopeni gelişen iki vakayı sunduk. Bu vakaları sunmaktaki amacımız linezolidin bu yan etkisi hakkında farkındalığı artırmaktır. Çünkü, linezolid tedavisi sırasında trombositopeni görülebileceği çok iyi bilinmesine karşın, bu yan etkinin gelişme riskinin böbrek fonksiyon bozukluğu olanlarda olmayanlara göre daha yüksek olduğu bilinmemektedir

Böbrek fonksiyon bozukluğu olan iki hastada linezolide bağlı trombositopeni

Linezolid is an oxazolidinone antibiotic, active against gram-positive bacteria that are resistant to other antibiotics including glycopeptides. Thrombocytopenia is an adverse effect of linezolid. Although various risk factors have been suggested, the mechanisms behind this side effect are largely unknown. Here, we report two adolescents with the diagnosis of chronic kidney disease who developed thrombocytopenia following treatment with linezolid. Our purpose in highlighting these cases is to increase the clinical awareness concerning this side effect of linezolid. While it is well known that thrombocytopenia may develop during linezolid treatment, it is relatively unknown that patients with renal dysfunction have an increased risk for the development of thrombocytopenia compared to patients without renal dysfunction

PDF

___

1.Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42:1007-12.
2.Champney WS, Miller M. Linezolid is a specific inhibitör of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol. 2002;44:350-6.
3.Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa Ket al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242-7.
4.Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki Het al.High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128-33.
5.Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YKet al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345-51.
6.Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42:66-72.
7.Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 2009;33:98-9.
8.Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775-80.
9.Slatter JG, Stalker DJ, Feenstra KL,Welshman IR, Bruss JB, Sams JPet al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136-45.
10.Cossu AP, Musu M, Mura P, De Giudici LM, Finco G. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol. 2014;70:23-8.
11.Niwa T, Watanabe T, Suzuki A, Ohmori T, Tsuchiya M, Suzuki Tet al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. Diagn Microbiol Infect Dis. 2014;79:93-7.
12.Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S et al. Risk factors associated with the development of thrombocytopenia in patients whoreceived linezolid therapy. J Infect Chemother. 2011;17:382-7.
13.Chen C, Guo DH, Cao X, Cai Y, Xu Y, Zhu M, Ma L. Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73:195-206.